Poolbeg Pharma (LON:POLB) Sets New 1-Year High – Here’s Why

Poolbeg Pharma PLC (LON:POLB) shares reached a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 9.20 and last traded at GBX 8.90, with a volume of 3011127 shares trading hands. The stock had previously closed at GBX 8.65.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research note on Monday, July 13th.

Poolbeg Pharma Price Performance

The firm has a fifty day simple moving average of GBX 7.20 and a 200 day simple moving average of GBX 5.68. The company has a market cap of £67.30 million, a price-to-earnings ratio of -9.38 and a beta of 1.80.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.